Rigontec was acquired by Merck for up to $554 million. The deal will expand Merck's cancer immunotherapy franchise using Rigontec's technology that activates retinoic acid-inducible gene I, which induces immediate and long-term antitumor immunity.
Rigontec purchased by Merck for $554M
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.